First Time Loading...

Qianjiang Yongan Pharmaceutical Co Ltd
SZSE:002365

Watchlist Manager
Qianjiang Yongan Pharmaceutical Co Ltd Logo
Qianjiang Yongan Pharmaceutical Co Ltd
SZSE:002365
Watchlist
Price: 8.3 CNY 0.73% Market Closed
Updated: May 6, 2024

Income Statement

Earnings Waterfall
Qianjiang Yongan Pharmaceutical Co Ltd

Revenue
1.1B CNY
Cost of Revenue
-758.9m CNY
Gross Profit
383.3m CNY
Operating Expenses
-359.9m CNY
Operating Income
23.3m CNY
Other Expenses
1.8m CNY
Net Income
25.1m CNY

Income Statement
Qianjiang Yongan Pharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Sep-2013 Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023
Revenue
Revenue
542
N/A
523
-4%
535
+2%
562
+5%
594
+6%
658
+11%
661
+0%
681
+3%
598
-12%
556
-7%
542
-3%
544
+1%
567
+4%
549
-3%
606
+10%
688
+14%
766
+11%
933
+22%
982
+5%
1 011
+3%
1 016
+0%
1 005
-1%
1 057
+5%
1 143
+8%
1 288
+13%
1 370
+6%
1 310
-4%
1 307
0%
1 252
-4%
1 173
-6%
1 268
+8%
1 304
+3%
1 407
+8%
1 565
+11%
1 664
+6%
1 680
+1%
1 563
-7%
1 462
-6%
1 361
-7%
1 214
-11%
1 142
-6%
Gross Profit
Cost of Revenue
(440)
(439)
(465)
(482)
(505)
(558)
(556)
(582)
(503)
(461)
(440)
(430)
(442)
(409)
(455)
(493)
(510)
(595)
(609)
(625)
(641)
(656)
(755)
(863)
(1 003)
(1 053)
(1 023)
(937)
(885)
(820)
(886)
(965)
(1 035)
(1 212)
(1 277)
(1 293)
(1 193)
(991)
(914)
(788)
(759)
Gross Profit
102
N/A
84
-17%
71
-16%
80
+12%
89
+12%
101
+14%
106
+5%
98
-7%
95
-3%
95
0%
102
+7%
114
+12%
125
+9%
141
+13%
152
+8%
196
+29%
256
+31%
338
+32%
373
+10%
387
+4%
374
-3%
350
-7%
302
-14%
281
-7%
284
+1%
318
+12%
287
-10%
370
+29%
367
-1%
353
-4%
382
+8%
338
-11%
372
+10%
354
-5%
387
+9%
387
+0%
370
-5%
471
+27%
447
-5%
426
-5%
383
-10%
Operating Income
Operating Expenses
(63)
(68)
(66)
(66)
(71)
(78)
(82)
(91)
(98)
(99)
(104)
(100)
(96)
(101)
(98)
(107)
(120)
(162)
(191)
(177)
(181)
(155)
(158)
(170)
(178)
(198)
(204)
(210)
(214)
(216)
(263)
(278)
(297)
(226)
(220)
(209)
(199)
(296)
(369)
(363)
(360)
Selling, General & Administrative
(64)
(63)
(64)
(62)
(64)
(69)
(74)
(81)
(88)
(88)
(95)
(95)
(93)
(91)
(94)
(103)
(115)
(111)
(163)
(170)
(170)
(128)
(148)
(146)
(145)
(143)
(139)
(149)
(154)
(171)
(201)
(215)
(241)
(169)
(172)
(163)
(156)
(252)
(303)
(293)
(290)
Research & Development
0
(1)
0
0
0
(2)
0
0
0
(2)
0
0
0
(1)
0
0
(2)
(47)
0
0
(7)
(24)
(18)
(35)
(45)
(54)
(49)
(46)
(44)
(47)
(55)
(54)
(54)
(50)
(50)
(49)
(47)
(37)
(40)
(42)
(44)
Depreciation & Amortization
0
(3)
0
0
0
(7)
0
0
0
(8)
0
0
0
(8)
0
0
0
(9)
0
0
0
(8)
0
0
0
(8)
0
0
0
(7)
0
0
0
(12)
0
0
0
(13)
0
0
0
Other Operating Expenses
1
(0)
(2)
(4)
(6)
(0)
(8)
(10)
(10)
(0)
(9)
(5)
(4)
(0)
(3)
(4)
(3)
4
(29)
(5)
(4)
5
9
11
12
7
(16)
(15)
(16)
10
(8)
(8)
(2)
4
2
2
4
6
(26)
(28)
(27)
Operating Income
39
N/A
16
-58%
5
-71%
14
+187%
18
+34%
23
+25%
23
+2%
8
-68%
(3)
N/A
(4)
-37%
(2)
+54%
14
N/A
29
+101%
40
+41%
54
+34%
89
+64%
137
+54%
176
+29%
182
+3%
210
+16%
193
-8%
195
+1%
144
-26%
111
-23%
106
-4%
119
+13%
83
-31%
160
+94%
153
-4%
137
-11%
119
-13%
61
-49%
75
+24%
128
+70%
167
+30%
178
+7%
170
-4%
176
+3%
78
-56%
63
-19%
23
-63%
Pre-Tax Income
Interest Income Expense
5
6
7
11
13
13
15
15
19
21
18
21
18
24
24
18
14
6
(2)
9
20
23
35
31
26
28
22
20
18
15
18
16
14
17
12
28
40
26
32
32
25
Non-Reccuring Items
0
0
0
0
0
(3)
0
0
0
(4)
0
0
0
(1)
0
(1)
(3)
(30)
0
(19)
(19)
(5)
0
(4)
(2)
(31)
0
0
(6)
(20)
0
0
0
(16)
0
0
1
(50)
0
(0)
(0)
Gain/Loss on Disposition of Assets
0
0
0
0
0
(1)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
5
5
6
4
4
6
5
6
6
7
8
11
13
11
15
12
9
5
(1)
(3)
(1)
(0)
(6)
(3)
(5)
0
5
1
(1)
(1)
(3)
(3)
(3)
1
(2)
(4)
(1)
1
1
(4)
(2)
Pre-Tax Income
48
N/A
28
-42%
17
-37%
28
+62%
35
+24%
37
+6%
42
+14%
29
-33%
22
-24%
21
-4%
25
+18%
46
+86%
59
+30%
73
+24%
93
+27%
119
+27%
157
+32%
157
N/A
180
+14%
198
+10%
194
-2%
212
+9%
172
-19%
133
-22%
125
-7%
116
-7%
110
-5%
181
+65%
165
-9%
131
-21%
134
+3%
74
-45%
86
+17%
130
+50%
177
+36%
202
+14%
209
+4%
153
-27%
111
-28%
91
-18%
46
-49%
Net Income
Tax Provision
(8)
(5)
(3)
(6)
(7)
(6)
(6)
(4)
(3)
(4)
(4)
(7)
(9)
(11)
(14)
(19)
(25)
(24)
(28)
(31)
(30)
(33)
(28)
(18)
(13)
(9)
(6)
(16)
(15)
(12)
(13)
(4)
(5)
(11)
(17)
(23)
(25)
(20)
(14)
(13)
(27)
Income from Continuing Operations
41
23
14
23
29
32
36
25
19
17
20
38
50
62
79
100
132
133
152
167
164
179
144
115
111
107
104
166
150
119
121
69
81
119
160
179
184
133
96
78
19
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
0
0
1
1
1
(0)
(4)
(10)
(15)
(17)
(16)
(15)
(15)
(13)
(13)
(11)
(8)
(8)
(6)
2
7
8
8
2
6
Net Income (Common)
41
N/A
23
-43%
14
-38%
23
+59%
29
+25%
32
+11%
36
+14%
25
-31%
19
-23%
18
-8%
21
+17%
39
+89%
50
+30%
62
+24%
79
+27%
100
+26%
132
+32%
133
+1%
152
+14%
168
+10%
164
-2%
179
+9%
140
-22%
106
-25%
97
-9%
90
-7%
88
-2%
151
+71%
135
-11%
106
-22%
108
+3%
59
-46%
73
+25%
111
+52%
154
+38%
181
+17%
191
+5%
140
-26%
105
-25%
80
-24%
25
-69%
EPS (Diluted)
0.15
N/A
0.08
-47%
0.05
-38%
0.08
+60%
0.1
+25%
0.11
+10%
0.12
+9%
0.08
-33%
0.06
-25%
0.06
N/A
0.07
+17%
0.14
+100%
0.18
+29%
0.22
+22%
0.28
+27%
0.35
+25%
0.46
+31%
0.47
+2%
0.53
+13%
0.59
+11%
0.55
-7%
0.61
+11%
0.49
-20%
0.36
-27%
0.32
-11%
0.31
-3%
0.3
-3%
0.51
+70%
0.46
-10%
0.37
-20%
0.37
N/A
0.2
-46%
0.27
+35%
0.38
+41%
0.5
+32%
0.64
+28%
0.65
+2%
0.48
-26%
0.37
-23%
0.27
-27%
0.09
-67%

See Also

Discover More